London Daily

Focus on the big picture.
Wednesday, Oct 22, 2025

Coronavirus: developing a vaccine is one problem to solve, getting people to use it is another

Coronavirus: developing a vaccine is one problem to solve, getting people to use it is another

Vaccination hesitancy may harm the chances of reopening communities. Medical experts say rapid vaccine development is causing public anxiety but wide-scale immunisation may be the only route back to a safe society
Shanghai mother Julia Wei has been closely following Covid-19 vaccine development updates. As a frequent business traveller, she believes an effective vaccine will be the key to a return to social and economic normalcy.

Yet as progress is made – four out of seven candidates developed in China are being tested for broader safety and efficacy before they can get regulatory approval– Wei said she and her six-year-old daughter would be unlikely to voluntarily get a Covid-19 jab. The public has been told a vaccine might be available as soon as the end of this year, or early next year.

“I read that vaccine development usually takes years, but for Covid-19 it’s only several months. This is just too fast – I don’t want to be a guinea pig,” Wei said. “I will just wait until we know for absolutely sure that they are safe and effective.”

Wei is not opposed to vaccines. She has had her daughter inoculated with free government vaccines as well as some that are not part of China’s immunisation programme that Wei believed were necessary.

But concerns such as Wei’s are casting a shadow over vaccination and its potential to reopen society or allow the community to reach “herd immunity”
– the concept that enough people in a population are immune to a disease that transmission becomes unlikely.

The hesitancy is shared in other countries. In a Gallup tracking survey released this month, over 35 per cent of Americans indicated they were reluctant to be vaccinated, even if a Covid-19 vaccine were approved by the US Food and Drug Administration and provided free.

A similar survey by the Angus Reid Institute in Canada showed that about 32 per cent of those surveyed were hesitant and would wait before getting vaccinated, while a further 14 per cent said they would not have the Covid-19 vaccine at all.

Even before the Covid-19 crisis, the World Health Organisation declared vaccination hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – one of the top 10 threats to global health last year.

Measles cases, for example, have jumped globally. Even though not all of these cases are because of vaccine hesitancy, some countries that were close to eliminating the disease have seen a resurgence.

“People are concerned because they keep hearing that the vaccines process is being so accelerated that our major vaccine programme is called Operation Warp Speed, almost implying something unnatural about how fast it is going,” said Margaret Hamburg, former commissioner of the US Food and Drug Administration in a webinar with Peking University three weeks ago.

“We also talked about manufacturing risk, which is really a financial risk because the governments and companies are actually investing resources in making vaccines in large numbers so that they can rapidly be deployed when those vaccines make it to the finishing line in terms of proving their benefit in safety and efficacy. But when people hear vaccines are made of risk that adds to the concerns.”

Vaccine experts say they understand why some people are hesitant, but that they should not be concerned about the development process.

There was no indication there would be short cuts in the vaccine approval and licensing process because FDA guidance on Covid-19 vaccines was clear and comprehensive, said Wilbur Chen, a professor of medicine at the University of Maryland School of Medicine.

“People should not have major concerns for the safety or effectiveness of Covid-19 vaccines if they are licensed on the basis of well-performed studies that adhere to the FDA’s guidelines,” Chen said.

It was possible that very rare adverse events would be detected only after a drug was licensed, which was not unique to Covid-19 vaccines but could apply to any drug or vaccine, Chen added.

Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said it was understandable that people were reluctant but he believed regulators in Britain or the European Union would not approve a vaccine without being presented with convincing evidence of efficacy, that it actually prevented Covid-19 infection and disease, rather than just triggering an immune response.

“I think that the speed is due to a number of factors and I do not see that the process has, so far at least, been deficient. Risks because of quick development would be almost entirely related to the numbers included in a trial,” Evans said. “What is required is sufficient numbers, both to show efficacy in preventing disease and in showing no serious harm.”

Apart from distrust in governments, institutions or aspects of immunisation, industry insiders said there was also complacency concern, the feeling that it might not be worth the trouble if there was no guarantee the vaccine protected against the virus. The target efficacy for Covid-19 vaccines is 50 per cent in China, the US and under the WHO guidelines, similar to the seasonal flu shot. And like flu shots, people might not think it is worth having the jab.

But according to experts, getting vaccinated is important not only for self-protection but also for the community. When a certain percentage of a population becomes immune to an infectious disease, usually through a vaccine, it creates a shield so that even if someone gets infected, the pathogen cannot be spread among the community, achieving herd immunity and protecting those who have not been vaccinated or who have a weakened immune system.

Jonathan Ball, a professor of molecular virology with the University of Nottingham, said the vaccine coverage needed for that herd immunity effect would be determined by its effectiveness. Does it prevent infection and/or onwards transmission or does it stop symptoms but still allow the spread?

“If the vaccine stops onwards transmission and the reproduction number [an indicator of contagiousness of a pathogen] is 3 then we would estimate that 66 per cent of vaccine coverage using a vaccine that is nearly 100 per cent effective would provide herd immunity and stop outbreaks,” Ball said. Many factors in the calculation remained unknown for now, he added.

Chen said that even if a vaccine was found to have moderate efficacy, using it would still help the community.

There could still be a lot of illness, medical care visits, hospital admissions and deaths avoided, so an “imperfect” vaccine could still have a significant effect in a population, he said.

“More people … taking the vaccine will improve that effect in the population. So vaccine hesitancy – or even failing to observe physical distancing, wearing masks and hand hygiene – will be an impediment or delay to safe reopening,” Chen said.

He said that for countries where Covid-19 was under control, vaccination still made sense because the situation had been achieved through short-term measures to cut off transmission – staying home, wearing masks, physical distancing and cancelling large gatherings. And even those nations still had occasional outbreaks.

“Therefore, the only long-term solution allowing the country to be able to safely reopen is wide-scale immunisation with effective vaccines,” Chen said.
Newsletter

Related Articles

0:00
0:00
Close
‘Frightening’ First Night in Prison for Sarkozy: Inmates Riot and Shout ‘Little Nicolas’
White House Announces No Imminent Summit Between Trump and Putin
US and Qatar Warn EU of Trade and Energy Risks from Tough Climate Regulation
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Nicolas Sarkozy begins five-year prison term at La Santé in Paris
Japan stocks surge to record as Sanae Takaichi becomes Prime Minister
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
Surging AI Startup Valuations Fuel Bubble Concerns Among Top Investors
Australian Punter Archie Wilson Tears Up During Nebraska Press Conference, Sparking Conversation on Male Vulnerability
Australia Confirms U.S. Access to Upgraded Submarine Shipyard Under AUKUS Deal
“Firepower” Promised for Ukraine as NATO Ministers Meet — But U.S. Tomahawks Remain Undecided
Brands Confront New Dilemma as Extremists Adopt Fashion Labels
The Sydney Sweeney and Jeans Storm: “The Outcome Surpassed Our Wildest Dreams”
Erika Kirk Delivers Moving Tribute at White House as Trump Awards Charlie Presidential Medal of Freedom
British Food Influencer ‘Big John’ Detained in Australia After Visa Dispute
ScamBodia: The Chinese Fraud Empire Shielded by Cambodia’s Ruling Elite
French PM Suspends Macron’s Pension Reform Until After 2027 in Bid to Stabilize Government
Orange, Bouygues and Free Make €17 Billion Bid for Drahi’s Altice France Telecom Assets
Dutch Government Seizes Chipmaker After U.S. Presses for Removal of Chinese CEO
×